Overall verdict
Sell
3.2/10
1-year performance
+27.27%
Score breakdown
Up 27.3% over 1 year, 9% of the 52-week range.
Strongest: Financial strength 8.7/10. Weakest: Shareholder return 0.0/10.
Sector
Health Care
Industry
Biotechnology
Primary listing
Krx
South Korea
CEO
—
Founded
2010
Employees
66
Revenue / employee
71.4M KRW
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
95800.00 KRW
52-week low
12000.00 KRW
1-year performance
27.27%
Rising
Year-to-date performance
-54.94%
Rising
Drawdown
-79.54%
Major drawdown
Position in the 52-week range
9% of range
Gross margin -3.2%, the company loses 328.3% of its revenue, ROIC -40.6%, ROE -57.8%.
Net margin
-328.26%
Negative
Sector -229.11%|S&P 12.97%
Gross margin
-3.19%
Negative
Return on equity (ROE)
-57.81%
Negative
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
-40.61%
Negative
Free cash flow margin (FCF)
-260.88%
Negative
Margin stability
217.1 pts
Very uneven
Growth
7.9/10Revenue up 51.4% over 1 year, 11.2% a year over 5.
Revenue (trailing 12 months)
4.9Md KRW
Revenue growth (1y)
51.44%
Hyper-growth
Revenue growth (3y)
38.39%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.30|S&P 0.86
Market cap
389Md KRW
Financial strength
8.7/10Cash covers 111.6% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
-13.54%
Net cash
Cash
33.8Md KRW
Cash / market cap
8.70%
Solid
Cash / total debt
111.59%
Net cash
Net debt
-3.5Md KRW
Equity
26.0Md KRW
Closed daily candles, 23 months
Last close on September 11, 2026: 20,500.00 KRW
- MM2025,340.00
- MM5024,441.00
- MM20043,248.25
- RSI 1437.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.76%
200-day average slope, 3 months
+6.87%
50-day average slope, 1 month
-7.22%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
5.10 % per day
Volatility change
-23.82%
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 3.2 | 2.9 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 1.7x | -3.3 % | 27.3 % |
